Close Menu

CHICAGO (GenomeWeb) – Sophia Genetics said that it has received a CE-IVD mark for a molecular diagnostics test designed to improve detection of leukemia and other hematological diseases. The Swiss company called this the "world’s first capture-based myeloid clinical solution" to receive this designation from European regulators.

The test is a sequencing-based assay combined with data analytics to detect mutations that cause myeloid and lymphoid leukemia.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
15
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing.